<h4>Background</h4>Adjuvant endocrine therapy is a cornerstone in managing estrogen receptor-positive early breast cancer but may adversely affect metabolic health, including weight gain, insulin resistance, and dyslipidemia. This evidence concerns the gene ESR1 and metabolic syndrome.